Nutex Health posts FY 2025 revenue of USD 875.3 million, up 82.4%

Reuters03-06
Nutex Health posts FY 2025 revenue of USD 875.3 million, up 82.4%

Nutex Health reported FY 2025 results with total revenue of USD 875.3 million (+82.4%), driven by its hospital division revenue of USD 844.2 million (+188.0%). Net income attributable to shareholders was USD 70.8 million, with diluted EPS of USD 10.48, EBITDA of USD 168.6 million (+70.6%) and adjusted EBITDA of USD 259.6 million (+152.6%). Net cash from operating activities was USD 248.1 million, and the company ended 2025 with cash and cash equivalents of USD 185.6 million and long-term debt, net of USD 29.2 million. In Q4 2025, total revenue was USD 151.7 million (-41.1%), which Nutex Health said primarily reflected a one-time USD 55.0 million cumulative true-up related to 18,950 arbitration claims deemed ineligible under the IDR process and the absence of USD 69.0 million in arbitration revenues that were recorded in Q4 2024. Q4 net income attributable to shareholders was USD 11.8 million, with EBITDA of USD 25.7 million (-67.4%) and adjusted EBITDA of USD 16.6 million (-80.8%). For corporate updates, Nutex Health said it opened three new micro-hospitals during 2025 and early 2026, remediated previously disclosed material weaknesses in internal controls over financial reporting in 2025, and noted it prevails in over 85% of IDR award determinations with an average collection rate of over 85% of determination wins. The board also authorized a second share repurchase program of up to USD 25.0 million over the next six months to offset dilution from future stock compensation obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutex Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-015174), on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment